Corcept Therapeutics (CORT) PT Lowered to $99 at Canaccord Genuity
Tweet Send to a Friend
Canaccord Genuity analyst Edward Nash lowered the price target on Corcept Therapeutics (NASDAQ: CORT) to $99.00 (from $140.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
